Medivir
BioStock: Medivir presents promising results in difficult-to-treat patient population
– We are particularly encouraged by the durable benefit, with patients remaining on treatment for much longer than expected. More than 10 months median time to progression is significantly longer than previously achieved with second-line treatment with Lenvima monotherapy or other treatment options, says Medivir's CEO Jens Lindberg.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se
| Datum | 2024-06-27, kl 10:00 |
| Källa | Cision |
Kom igång med ditt sparande på bara några minuter! Hos Avanza handlar du aktier från 0 kr på Stockholmsbörsen och får tillbaka alla fondavgifter (ja, alla!) upp till 50 000 kr i samlat sparande. Kanske är det därför Avanza har Sveriges nöjdaste sparare 15 år i rad.
Investeringar innebär en risk